89, p=0.57) differed between the groups. On subset analysis, patient

with squamous cell tumors had a better progression-free survival with CRT (HR 0.47, p=0.014) than those with non-squamous tumors (HR=1.02, p=0.92). Weaknesses of this trial included administration of only one cycle of chemotherapy and relatively low radiation doses. INK 128 concentration Multiple trials have evaluated preoperative chemoradiation therapy with some improvement in survival outcomes and notable pathological complete response rates as detailed in Table 2. Table 2 Trials of preoperative chemoradiotherapy Preoperative chemoradiotherapy versus definitive chemoradiotherapy Some authorities Inhibitors,research,lifescience,medical believe that the role of surgery for squamous cell carcinomas remains controversial based on two studies, one from France and another from Germany. The Federation Francophone Inhibitors,research,lifescience,medical de Cancerologie Digestive Study 9102 enrolled 444 patients with resectable squamous cell carcinoma (89%) or adenocarcinoma (11%), to receive one of two radiation schemes with 2 courses of concurrent cisplatin Inhibitors,research,lifescience,medical and 5-FU: 1) protracted radiotherapy (46 Gy over 4.5 weeks) (64% of participants)

or 2) split course radiotherapy with two 1-week courses of 15 Gy with a 2 week break (36%) (17). 259 patients who responded to therapy were randomly assigned to surgery or additional chemoradiation. For the non-responders, they continued on a course of CRT with an additional 20 Gy for the protracted course and 15 Gy for the split course CRT. No significant differences were seen in median survival and (17.7 months in those who underwent surgery compared to Inhibitors,research,lifescience,medical 19.3 months in the definitive CRT arm) 2-year survival (34% in surgery cohort vs 40% in the CRT arm, p=0.44). Nevertheless, the 2-year local control rate was higher with surgery (66%) compared to CRT (57%). The 3-month mortality rate was 9% in the surgery group and 1% in the CRT group. The results of this trial imply that for patients who respond to CRT, surgery may improve local control but not survival. In a similar Inhibitors,research,lifescience,medical study design by Stahl et al, 172 patients with locally advanced squamous

Sodium butyrate cell carcinoma of the esophagus were randomized to either induction chemotherapy (5-FU, leucovorin, etoposide, and cisplatin for 3 cycles) followed by CRT (40 Gy with cisplatin and etoposide) followed by surgery or the same induction chemotherapy followed by CRT (total dose of 60-65 Gy with or without brachytherapy) without surgery (18). Overall survival at 2-years (40% with surgery vs 35% with CRT) and median survivals (16 months vs 15 months) were equivalent. Freedom from local progression was improved with surgery (64% vs 41%, p=0.003). Surgery improved outcomes for non-responders to CRT who had 3-year survival rates of 18% with surgery compared to 9% with CRT alone. Treatment related mortality was also higher in the surgery arm (13% vs 3.5%, p=0.03).